Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Patient with non-resectable metastatic colorectal cancer with histological or cytological documentation of adenocarcinoma of the colon or rectum. * Patient in third line or fourth line of treatment for metastatic colorectal cancer. * Patient with measurable lesions according to RECIST criteria (version 1.1). * Patient with ECOG equal to or less than 2. * Patient with adequate organ function * Other inclusion criteria may also apply Exclusion Criteria: * Prior treatment with masitinib, or any other tyrosine kinase inhibitor for the treatment of malignancy, except regorafenib. * More than 3 prior chemotherapy regimens for metastatic colorectal cancer. * Pregnant, intent to be pregnant, or nursing female patient * Patient with any chronic inflammatory bowel disease * Patient treated for a cancer other than colorectal cancer within five years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ. * Other exclusion criteria may also apply